Figure 4.
Id1/3-PA7 induces cycle arrest and apoptosis in ovarian cancer cells. (A–J) Quantification of cell-incorporated bromodeoxyuridine (BrdU) (fluorescein isothiocyanate (FITC) anti-BrdU) and total DNA content (7-AAD) in untreated and TrxA-treated (5 μg per 106 cells) or Id1/3-PA7-treated (5 μg per 106 cells) ES-2 cells (A, C) and PA-1 cells (D–F). Flow cytometric analysis of untreated cells vs Id1/3-PA7-treated cells showed S-phase reduction of actively cycling ES-2 cells (G) and PA-1 cells (I), increasing apoptotic cells in sub-G0/G1- and G2/M-resided ES-2 cells (H) and PA-1 cells (J). There were no significant differences between untreated and TrxA-treated cells (A–J). Bars: black, untreated; white dotted, TrxA treated; hatched, Id1/3-PA7 treated. Results are represented as mean values of three independent experiments with s.d. (P⩽0.05).